Home/Filings/4/0001209191-20-004717
4//SEC Filing

Prentiss Christopher B 4

Accession 0001209191-20-004717

CIK 0001328143other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 5:33 PM ET

Size

5.3 KB

Accession

0001209191-20-004717

Insider Transaction Report

Form 4
Period: 2020-01-21
Prentiss Christopher B
Chief Accounting Officer
Transactions
  • Sale

    Common Stock

    2020-01-21$5.92/sh1,269$7,51270,940 total
Footnotes (2)
  • [F1]Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
  • [F2]The shares were sold at prices ranging from $5.90 to $5.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Issuer

Adamas Pharmaceuticals Inc

CIK 0001328143

Entity typeother

Related Parties

1
  • filerCIK 0001717583

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 5:33 PM ET
Size
5.3 KB